Bioatla (BCAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Jun, 2026Executive summary
Annual Meeting scheduled for July 16, 2026, to be held virtually at 8:00 a.m. PST.
Proxy materials and annual report are available online, with options for paper or email copies upon request.
Stockholders can vote online, by phone, or during the virtual meeting using a unique control number.
Voting matters and shareholder proposals
Election of two Class III directors, Jay M. Short, Ph.D., and Edward Williams, for three-year terms expiring at the 2029 Annual Meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation for named executive officers.
Provision to transact any other business that may arise during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all three main proposals presented at the meeting.
Latest events from Bioatla
- Shareholders will vote on director elections, auditor ratification, and executive pay, all recommended for approval.BCAB
Proxy filing3 Jun 2026 - Net loss narrowed, cash remains low, and strategic review continues amid going concern risks.BCAB
Q1 202615 May 2026 - CAB platform delivers tumor-selective therapies with strong efficacy and safety in solid tumors.BCAB
Investor presentation31 Mar 2026 - Net loss of $59.6M in 2025, cash runway through H1 2026, and a 70% workforce reduction amid strategic review.BCAB
Q4 202531 Mar 2026 - Stockholders to vote on a merger and share conversion at a reconvened meeting on March 23, 2026.BCAB
Proxy Filing2 Mar 2026 - Shareholders to vote on a 1-for-50 share consolidation to address Nasdaq listing compliance.BCAB
Proxy Filing11 Feb 2026 - Q2 2024 saw reduced net loss, clinical milestones, and cash runway through Q3 2025.BCAB
Q2 20242 Feb 2026 - Promising clinical data and pivotal trial plans drive optimism for CAB-based cancer therapies.BCAB
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Vote on a 1-for-50 share consolidation merger to regain Nasdaq compliance and update governance.BCAB
Proxy Filing30 Jan 2026